Clinical analysis of 10 cases of advanced esophageal carcinoma treated with radioactive gastric tube of 125Ⅰ seeds
10.3760/cma.j.issn.0254-5098.2017.10.006
- VernacularTitle:放射性125Ⅰ粒子胃管治疗晚期食管癌10例临床分析
- Author:
Wen SUN
1
;
Hongxin NIU
;
Xikun ZHANG
;
Bin WANG
;
Huangang YANG
;
Feng ZHONG
;
Lin SUN
;
Jian WANG
;
Liang HAO
;
Wentao SONG
Author Information
1. 山东省医学科学院附属医院微创外科
- Keywords:
Esophageal carcinoma;
125Ⅰ seed;
Gastric tube;
Intracavitary brachytherapy
- From:
Chinese Journal of Radiological Medicine and Protection
2017;37(10):752-757
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the feasibility, safety and preliminary efficacy of radioactive gastric tube of 125Ⅰ seeds in the treatment of advanced esophageal carcinoma. Methods For 10 cases with advanced esophageal carcinoma, the tumor target area was outlined in the TPS system according to preoperative CT images. Prescription dose was 60 Gy with 125Ⅰ seed radioactivity of 2. 22 × 107 Bq. Accordingly, the 125Ⅰ seeds number and the appropriate gastric tube was decided. Then, depending on the location of the tumor and certain rules, 125Ⅰ seeds were fixed in the tube wall to make the radioactive 125Ⅰ seeds gastric tube. Under the C-arm X-ray fluoroscopy, the radioactive 125Ⅰ seeds gastric tubes were placed into esophageal carcinoma site of the patients. Results The radioactive 125Ⅰ seeds gastric tubes of 10 patients were successfully placed, without esophageal perforation, bleeding complications and so on. In one month after operation, all patients with dysphagia′s Stooler classification score were 2 -3 level,of which one case died of other basic diseases in three months after operation, and six cases achieved 0 -1 level while the other three cases achieved 1 -2 level in four months after operation. There were no cases of postoperative chest pain, bleeding, pneumonia and other related complications. Conclusions The radioactive 125Ⅰ seeds gastric tube could not only help to solve nutrition problems, but also the intracavitary brachytherapy inhibit the growth of tumor, which is safe and feasible in clinical use. It can be used as a palliative treatment for patients with advanced esophageal carcinoma.
